4.7 Review

Drugging the HDAC6-HSP90 interplay in malignant cells

期刊

TRENDS IN PHARMACOLOGICAL SCIENCES
卷 35, 期 10, 页码 501-509

出版社

ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2014.08.001

关键词

Acetylation; cancer; HDAC6; HDAC6 inhibitor; HSP90; leukemia

资金

  1. Deutsche Forschungsgemeinschaft [KR 2291/4-1/MA 2183/1-1]
  2. German Cancer Aid [110909, 110125]
  3. Wilhelm Sander-Stiftung [2010.078.2]
  4. intramural fundings

向作者/读者索取更多资源

Acetylation and deacetylation cycles regulate crucial biological processes. The enzymes deacetylating lysine residues are termed histone deacetylases (HDACs). Eighteen deacetylases have been isolated from mammalian cells. There is an intense search underway for individual functions of these enzymes and for selective histone deacetylase inhibitors (HDACi). HDAC6 in particular has unique cytoprotective functions that rely on its ability to ensure protein homeostasis and to prevent protein aggregation. The chaperone heat shock protein 90 (HSP90) also safeguards proteins and is deacetylated by HDAC6. Current data illustrate the complexity and importance of the HDAC6-HSP90 interplay. In this review, we discuss how recently identified HSP90-dependent regulators of post-translational modifications (PTMs) of HDAC6 dictate its functions, and how HDACi-induced acetylation of HSP90 might control oncologically relevant proteins, especially in leukemic cells. Additionally, we discuss small molecules blocking HDAC6 and how such agents could become therapeutically relevant. We summarize structure-function relationships that determine the specificity of drugs against HDAC6.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据